Trevogrumab
Anti-myostatin antibody · Also known as REGN1033
What is Trevogrumab?
A fully human monoclonal antibody that neutralizes myostatin. Developed by Regeneron Pharmaceuticals for age-related muscle loss (sarcopenia) and muscular dystrophy.
Trevogrumab (REGN1033) binds to and neutralizes circulating myostatin. Regeneron has been studying it in combination with other therapies for muscle wasting conditions. It represents a pharmaceutical-grade approach to myostatin inhibition.
Benefits & evidence
How it works
Trevogrumab is a monoclonal antibody that binds specifically to myostatin with high affinity, preventing it from interacting with its receptor (ActRIIB) on muscle cells. With myostatin signaling blocked, muscle protein synthesis increases and degradation decreases.
Unlike decoy receptors like ACE-031, antibodies are highly specific to a single target, potentially reducing off-target effects on other TGF-beta family members. Regeneron is studying it both alone and in combination with other muscle-targeting therapies.
Dosing information
Typical dosing protocol
Not publicly available
Not publicly available
Only available through clinical trials. Not commercially available as a research peptide.
Side effects
Most side effects tend to improve as your body adjusts.